

**University of Miami/Jackson Memorial Hospital (Main)**  
**ANTIBIOTIC SUSCEPTIBILITY REPORT January - June 2013**

Data include 1<sup>st</sup> isolate from patient (JMH Central)

T.J. Cleary, PhD (305 585-7851)

CLSI M100-S22, 2012 breakpoints

GRAM-NEGATIVE ISOLATES	No.	Percent susceptible												
		AM	AMC	CZ	FOX	CRO	FEP	ERT	MER	AN	GM	TOB	LVX	SXT
Escherichia coli	1379	27	70	74	84	86	97	99	99	99	83	83	58	51
Citrobacter freundii	53	/	/	/	/	/	91	99	99	99	90	92	87	81
Citrobacter koseri	45	/	99	96	91	99	99	99	99	99	98	98	98	98
Klebsiella pneumoniae	545	/	78	/	88	81	95	99	97	99	86	84	81	76
Enterobacter aerogenes	56	/	/	/	/	/	98	96	98	98	96	96	96	89
Enterobacter cloacae	170	/	/	/	/	/	96	98	97	99	97	97	92	88
Serratia marcescens	74	/	/	/	/	/	99	99	97	99	95	91	92	98
Proteus mirabilis	226	72	99	64	92	98	99	98	98	99	95	97	83	82
Morganella morganii	50	/	/	/	/	/	96	99	94	98	84	82	66	56
Providencia stuartii	19	/	/	/	/	90	99	95	99	99	/	/	58	79
Pseudomonas aeruginosa	365	/	/	/	/	/	82	/	66	97	85	93	61	/
Acinetobacter baumannii	125	/	/	/	/	/	/	/	59	86	55	76	46	48
Stenotrophomonas maltophilia	119	/	/	/	/	/	/	/	/	/	/	/	81	81

AM AMPICILLIN  
 AMC AMOX/CLAVANIC ACID  
 AN AMIKACIN  
 CEF CTX or CRO  
 CIP CIPROFLOXACIN  
 CLN CLINDAMYCIN  
 CRO CEFTRIAZONE  
 CTX CEFOTAXIME  
 CZ CEFAZOLIN  
 ERT ERTAPENEM  
 ERY ERYTHROMYCIN  
 FEP CEFEPIME  
 FOX CEFOXITIN  
 GM GENTAMICIN  
 IMP IMIPENEM  
 LVX LEVOFLOXACIN  
 LZD LINEZOLID  
 OX OXACILLIN  
 PEN PENICILLIN  
 RIF RIFAMPIN  
 SYN QUINUPRIS/DALFO  
 SXT TRIMETH/SULFA  
 TE TETRACYCLINE  
 TOB TOBRAMYCIN  
 VA VANCOMYCIN

( / ) slash indicates that the drug is clinically ineffective or <20% susceptible (Sanford Guide to Antimicrobial Therapy, 2012)

GRAM-POSITIVE ISOLATES	No.	Percent susceptible													
		PEN	OX	CZ	CEF	CLN	ERY	GM	LVX	RIF	TE	SYN	LZD	VA	SXT
Enterococcus faecalis	362	94	/	/	/	/	/	/	74	/	19	/	99	94	/
Enterococcus faecium	100	15	/	/	/	/	/	/	/	/	17	97	99	22	/
Staph aureus MRSA <sup>a</sup>	475	0	0	0	0	58	11	94	21	98	88	88	100	100	90
Staph aureus MSSA <sup>a</sup>	405	2	100	100	100	81	64	98	92	99	85	84	100	100	97
Staphylococcus epidermidis <sup>a</sup>	293	0	21	21	/	41	21	66	/	97	84	/	100	99	39
Staphylococcus haemolyticus <sup>a</sup>	66	0	29	29	/	62	21	77	/	98	62	/	100	99	64
Staphylococcus hominis <sup>a</sup>	46	2	30	30	/	41	24	87	/	98	70	/	100	100	46
Streptococcus agalactiae	88	100	/	/	/	84	69	/	99	/	/	100	100	100	/
Streptococcus pneumoniae <sup>b,c</sup>	35	88	/	/	78	71	60	/	100	/	/	/	100	100	66

- (a) S. aureus and coagulase-negative staph (CNS) resistant to oxacillin are resistant to penicillins, cephalosporins, and carbapenems overall MRSA = 54% of all Staphylococcus aureus isolates
- (b) Streptococcus pneumoniae: 31 isolates (88%) were susceptible to penicillin (MIC ≤2.0 ug/ml) by CLSI parenteral breakpoints for non-meningeal infections
- (c) Streptococcus pneumoniae: 27 isolates (77%) were susceptible to cefotaxime or ceftriaxone (MIC ≤1.0 ug/ml) by CLSI parenteral breakpoints for non-meningeal infections